Understanding how gut bacteria affect Type 2 Diabetes risk
Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk
This study is trying to see how changes in gut bacteria might affect blood sugar control in people with Type 2 Diabetes compared to those without it.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Laval University Academic / other |
| Locations | 1 site (Québec, Quebec) |
| Trial ID | NCT04579900 on ClinicalTrials.gov |
What this trial studies
This study investigates the relationship between gut microbiota and Type 2 Diabetes (T2D) by examining how changes in gut bacteria may influence glucose control and insulin sensitivity. It aims to identify specific bacterial strains that contribute to dysbiosis and potentially disrupt the gut barrier in individuals with T2D. Through endoscopy and duodenal biopsy, researchers will collect samples from both T2D patients and non-T2D individuals to compare microbial signatures and understand their role in metabolic dysfunction.
Who should consider this trial
Good fit: Ideal candidates for this study include individuals diagnosed with Type 2 Diabetes or those who are not diagnosed but are at risk.
Not a fit: Patients currently taking oral hypoglycemic agents, lipid-lowering, or antihypertensive drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or managing Type 2 Diabetes by targeting gut microbiota.
How similar studies have performed: Other studies have shown promising results in understanding the role of gut microbiota in metabolic diseases, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * T2DB de novo or non T2DB patients Exclusion Criteria: * oral hypoglycemic agents or lipidlowering or antihypertensive drugs
Where this trial is running
Québec, Quebec
- INAF, Université Laval — Québec, Quebec, Canada (Recruiting)
Study contacts
- Principal investigator: André Marette, PhD — Laval University
- Study coordinator: Geneviève Pilon, PhD
- Email: Genevieve.Pilon@criucpq.ulaval.ca
- Phone: 418-656-8711
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.